MedPath

Effect of Short-term Annatto Carotenoids Supplementation on Oxidative Stress Status in Healthy Individuals

Not Applicable
Completed
Conditions
Oxidative Stress
Atherosclerosis
Interventions
Dietary Supplement: Bixin
Dietary Supplement: Lycopene
Dietary Supplement: Placebo
Dietary Supplement: Norbixin
Registration Number
NCT03820245
Lead Sponsor
Universidade Federal de Santa Maria
Brief Summary

Low-density lipoprotein (LDL) oxidation has a pivotal role in atherosclerosis development. There is a relationship between carotenoids serum concentration and cardiovascular (CV) benefits, mainly in oxidized LDL (oxLDL) reduction. Despite cardio protective effects of annatto carotenoids, bixin and norbixin, in vitro and in animal studies, its short or long-term supplementation effect on humans are not know. Objective: To analyse CV benefits of annatto carotenoids short-term supplementation in healthy individuals, comparing to lycopene effect. Methods: 16 healthy volunteers (8 men and 8 women) consumed 0.05 mg/kg b.w. of each treatment (bixin, norbixin, lycopene or placebo) through capsules, during 7 days. It was analysed the susceptibility of LDL to Cu2+-induced oxidation, biochemical parameters and oxidative stress biomarkers at the beginning and end of each treatment.

Detailed Description

Graduate and post-graduate students were recruited in Federal University of Santa Maria to study participation. First, the health status of volunteers was analysed by questioner application (to evaluate lifestyle, family history, individual characteristics), anthropometric (height, weight, waist circumference) and biochemical parameters (glucose, lipid profile, transaminases, urea, creatinine) measurements. According to inclusion criteria, 18 volunteers were able to study participation, but just 16 people remained until the end of the study.

Each treatment was composed by 7 capsules (containing 0.05 mg carotenoid or placebo/kg b.w.) which should be consumed once a day (preferably in the morning), during 7 days. It was conducted a randomized, double blind, placebo-controlled crossover clinical trial, where 16 participants received 4 proposed treatments (bixin, norbixin, lycopene and placebo) in different periods. To plasma, serum and red blood cells (RBC) obtainment, 2 fasting blood collections were made, in the beginning (Day 0) and the end (Day 7) of each treatment. These samples were used for evaluating the ex vivo oxidation of LDL induced by copper sulphate and biochemical and oxidative biomarkers measurements.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
16
Inclusion Criteria
  • Normal levels of glucose, lipid profile, transaminases, urea and creatine
  • Normal blood pressure, weight and body mass index (BMI)
Exclusion Criteria
  • Chronic diseases (diabetes, dyslipiademia, hypertension cancer, etc.)
  • Drug, alcohol and cigarette consumption/addiction
  • Medication, vitamins or suplements consumption (except oral contraceptive used by women)
  • Recent inflammatory/infectious diseases

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
BixinBixinConsumption of 0.05 mg bixin/kg b.w. through capsules (once a day) by 7 days in the morning.
LycopeneLycopeneConsumption of 0.05 mg lycopene/kg b.w. through capsules (once a day) by 7 days in the morning.
PlaceboPlaceboConsumption of 0.05 mg placebo/kg b.w. through capsules (once a day) by 7 days in the morning.
NorbixinNorbixinConsumption of 0.05 mg norbixin/kg b.w. through capsules (once a day) by 7 days in the morning.
Primary Outcome Measures
NameTimeMethod
Evaluation of LDL lipid moiety susceptibility to copper induced oxidation - oxidation rateDay 0 and Day 7

Change (Day 7 - Day 0) of oxidation rate of conjugated dienes formed after copper sulphate addition to LDL particles

Evaluation of LDL lipid moiety susceptibility to copper induced oxidation - lag phaseDay 0 and Day 7

Change (Day 7 - Day 0) of lag phase time of conjugated dienes formed after copper sulphate addition to LDL particles

Evaluation of LDL protein moiety susceptibility to copper induced oxidationDay 0 and Day 7

Evaluate the change (Day 7 - Day 0) of loss of tryptophan fluorescence after oxidation induced by copper

Secondary Outcome Measures
NameTimeMethod
Evaluation of red blood cell osmotic fragilityDay 7

Change of red blood cell osmotic fragility after ex vivo exposure to membrane damage inducers

Evaluation of protein oxidationDay 0 and Day 7

Change at advanced oxidation protein products levels in plasma

Evaluation of lipid oxidationDay 0 and Day 7

Change at malondialdehyde levels in plasma and red blood cells

Evaluation of nitric oxide metabolitesDay 0 and Day 7

Change at nitric oxide metabolites levels in serum

Evaluation of gluthatione cycleDay 0 and Day 7

Change at reduced glutathione/oxidized glutathione ratio in red blood cells

Evaluation of carotenoids levelsDay 0 and Day 7

Change at carotenoids levels in plasma and red blood cells

Evaluation of plasma antioxidant capacityDay 0 and Day 7

Change at oxygen radical absorbance capacity in plasma

Evaluation of enzymatic antioxidant defencesDay 0 and Day 7

Change at antioxidant enzymes activities in red blood cells

Trial Locations

Locations (1)

Universidade Federal de Santa Maria

🇧🇷

Santa Maria, Rio Grande Do Sul, Brazil

© Copyright 2025. All Rights Reserved by MedPath